BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33183422)

  • 1. Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway.
    Liu Y; Hu F; Zhao L
    J Nanosci Nanotechnol; 2021 Feb; 21(2):903-908. PubMed ID: 33183422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Versatile Pt NCs-based chemotherapeutic agents significantly induce the apoptosis of cisplatin-resistant non-small cell lung cancer.
    Xin Y; Huang X; Li Z; Zhao W; Wang C; Wang S; Yue X; Mo H; Li H
    Biochem Biophys Res Commun; 2019 Apr; 512(2):218-223. PubMed ID: 30885437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
    Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
    Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549/Cis cells through c-Myc/p53 and Bcl-2/caspase-3 signaling pathways.
    Zhao L; Li H; Huang X; Liu T; Xin Y; Xiao Z; Zhao W; Miao S; Chen J; Li Z; Mi Y
    Biomed Pharmacother; 2021 Dec; 144():112360. PubMed ID: 34794242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing
    He L; Du ZD; Wang Y; Meng RQ; Zhao WW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):312-319. PubMed ID: 32543135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
    Feng X; Liu H; Zhang Z; Gu Y; Qiu H; He Z
    J Exp Clin Cancer Res; 2017 Sep; 36(1):123. PubMed ID: 28886730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
    Tian W; Sun Y; Cheng Y; Ma X; Du W; Shi W; Guo Q
    Thorac Cancer; 2021 Oct; 12(19):2551-2563. PubMed ID: 34469060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
    Feng FF; Cheng P; Sun C; Wang H; Wang W
    Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
    Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
    Mattheolabakis G; Ling D; Ahmad G; Amiji M
    Pharm Res; 2016 Dec; 33(12):2943-2953. PubMed ID: 27528390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549.
    He Y; Fan SZ; Jiang YG
    Ai Zheng; 2006 Aug; 25(8):925-32. PubMed ID: 16965670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
    Hu Z; Zeng Q; Zhang B; Liu H; Wang W
    Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
    Xia Y; He Z; Liu B; Wang P; Chen Y
    Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIAA0101 promotes cisplatin resistance through regulating cell apoptosis in lung cancer cells.
    Zhang C; Liu Y; Zhao J; Xu J; Pei B; Liu X; Yue X
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):172-176. PubMed ID: 38279448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.